-
Je něco špatně v tomto záznamu ?
The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis
S. Ganjali, GF. Watts, M. Banach, Ž. Reiner, P. Nachtigal, A. Sahebkar
Jazyk angličtina Země Spojené arabské emiráty
Typ dokumentu časopisecké články, přehledy
- MeSH
- ateroskleróza * MeSH
- celogenomová asociační studie MeSH
- cholesterol MeSH
- HDL-cholesterol MeSH
- kardiovaskulární nemoci * MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
The inverse relationship between low plasma high-density lipoprotein cholesterol (HDL-C) concentrations and increased risk of Atherosclerotic Cardiovascular Disease (ASCVD) is well-known. However, plasma HDL-C concentrations are highly variable in subjects with ASCVD. In clinical outcome trials, pharmacotherapies that increase HDL-C concentrations are not associated with a reduction in ASCVD events. A causal relationship between HDL-C and ASCVD has also been questioned by Mendelian randomization studies and genome-wide association studies of genetic variants associated with plasma HDL-C concentrations. The U-shaped association between plasma HDL-C concentrations and mortality observed in several epidemiological studies implicates both low and very high plasma HDL-C concentrations in the etiology of ASCVD and non- ASCVD mortality. These data do not collectively support a causal association between HDL-C and ASCVD risk. Therefore, the hypothesis concerning the association between HDL and ASCVD has shifted from focus on plasma concentrations to the concept of functionality, in particular cellular cholesterol efflux and HDL holoparticle transport. In this review, we focus on these new concepts and provide a new framework for understanding and testing the role of HDL in ASCVD.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026233
- 003
- CZ-PrNML
- 005
- 20211026133106.0
- 007
- ta
- 008
- 211013s2021 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/0929867328666210208182326 $2 doi
- 035 __
- $a (PubMed)33563147
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a Ganjali, Shiva $u Department of Medical Biotechnology and Nanotechnology, Mashhad University of Medical Sciences, Mashhad, Iran
- 245 14
- $a The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis / $c S. Ganjali, GF. Watts, M. Banach, Ž. Reiner, P. Nachtigal, A. Sahebkar
- 520 9_
- $a The inverse relationship between low plasma high-density lipoprotein cholesterol (HDL-C) concentrations and increased risk of Atherosclerotic Cardiovascular Disease (ASCVD) is well-known. However, plasma HDL-C concentrations are highly variable in subjects with ASCVD. In clinical outcome trials, pharmacotherapies that increase HDL-C concentrations are not associated with a reduction in ASCVD events. A causal relationship between HDL-C and ASCVD has also been questioned by Mendelian randomization studies and genome-wide association studies of genetic variants associated with plasma HDL-C concentrations. The U-shaped association between plasma HDL-C concentrations and mortality observed in several epidemiological studies implicates both low and very high plasma HDL-C concentrations in the etiology of ASCVD and non- ASCVD mortality. These data do not collectively support a causal association between HDL-C and ASCVD risk. Therefore, the hypothesis concerning the association between HDL and ASCVD has shifted from focus on plasma concentrations to the concept of functionality, in particular cellular cholesterol efflux and HDL holoparticle transport. In this review, we focus on these new concepts and provide a new framework for understanding and testing the role of HDL in ASCVD.
- 650 12
- $a ateroskleróza $7 D050197
- 650 12
- $a kardiovaskulární nemoci $7 D002318
- 650 _2
- $a cholesterol $7 D002784
- 650 _2
- $a HDL-cholesterol $7 D008076
- 650 _2
- $a celogenomová asociační studie $7 D055106
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Watts, Gerald F $u Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital, School of Medicine, University of Western Australia, Perth, Western Australia, Australia
- 700 1_
- $a Banach, Maciej $u Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland
- 700 1_
- $a Reiner, Željko $u University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Department of Internal Medicine, Zagreb, Croatia
- 700 1_
- $a Nachtigal, Petr $u Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Sahebkar, Amirhossein $u Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
- 773 0_
- $w MED00001274 $t Current medicinal chemistry $x 1875-533X $g Roč. 28, č. 29 (2021), s. 6066-6081
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33563147 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133112 $b ABA008
- 999 __
- $a ok $b bmc $g 1715060 $s 1146740
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 28 $c 29 $d 6066-6081 $e - $i 1875-533X $m Current medicinal chemistry $n Curr Med Chem $x MED00001274
- LZP __
- $a Pubmed-20211013
